This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Traws Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.012. Traws Pharma's 10-Year median PS Ratio is 23.3333. Therefore, the Median PS Value for today is $0.28.
As of today (2024-04-29), Traws Pharma's share price is $0.64495. Traws Pharma's Median PS Value is $0.28. Therefore, Traws Pharma's Price to Median PS Value for today is 2.30.
The historical rank and industry rank for Traws Pharma's Median PS Value or its related term are showing as below:
TRAW'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 2.19 Med: 2.66 Max: 2.66
Current: 2.3
During the past 13 years, the highest Price to Median PS Value of Traws Pharma was 2.66. The lowest was 2.19. And the median was 2.66.
TRAW's Price-to-Median-PS-Value is ranked worse than 89.19% of 259
companies
in the Biotechnology industry
Industry Median: 0.65
vs TRAW: 2.30
Traws Pharma Median PS Value Historical Data
The historical data trend for Traws Pharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Traws Pharma's Median PS Value
For the Biotechnology subindustry, Traws Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Traws Pharma's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Traws Pharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Traws Pharma's Price-to-Median-PS-Value falls into.
Traws Pharma Median PS Value Calculation
Traws Pharma's Median PS Value for today is calculated as
10-Year Median PS Ratio is 23.3333.
Traws Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.012.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma (NAS:TRAW) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Traws Pharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.64495
/
0.28
=
2.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma Median PS Value Related Terms
Thank you for viewing the detailed overview of Traws Pharma's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TRAW has been successfully added to your 